Literature DB >> 6816283

Multiple forms of iduronate 2-sulphate sulphatase in human tissues and body fluids.

I M Archer, P S Harper, F S Wusteman.   

Abstract

Iduronate 2-sulphate sulphatase (EC 3.1.6.-) was found in human placenta in three forms which could be separated by elution from DEAE-cellulose using an NaCl gradient. Form C, most firmly bound to DEAE-cellulose, was 40% larger than the other two (forms A and B in order of ease of elution from the ion exchanger). Forms B and C contained sialic acid which could be removed by neuraminidase digestion. After removal of sialic acid form B became indistinguishable from form A. The enzyme forms found in placenta were compared with those from other human tissues and fluids by means of DEAE-cellulose chromatography and gel chromatography. Serum and amniotic fluid contained only form C, urine and cultured fibroblasts contained the less-anionic forms as well, and kidney contained appreciable amounts only of form A. Pre- and post-natal diagnosis of the Hunter syndrome both involve measurements on the enzyme which is present in form C. This is not accompanied by less-anionic forms which constitute the bulk of the enzyme as it is isolated from easily available sources such as urine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6816283     DOI: 10.1016/0167-4838(82)90213-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin.

Authors:  Femke-Anouska Heinsen; Henrik Knecht; Sven C Neulinger; Ruth A Schmitz; Carolin Knecht; Tanja Kühbacher; Philip C Rosenstiel; Stefan Schreiber; Anette K Friedrichs; Stephan J Ott
Journal:  Gut Microbes       Date:  2015-07-04

2.  Hunter syndrome: prenatal diagnosis in maternal serum.

Authors:  J Zlotogora; G Bach
Journal:  Am J Hum Genet       Date:  1986-02       Impact factor: 11.025

3.  Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties.

Authors:  J Bielicki; C Freeman; P R Clements; J J Hopwood
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

4.  Low-scale expression and purification of an active putative iduronate 2-sulfate sulfatase-Like enzyme from Escherichia coli K12.

Authors:  Edwin David Morales-Álvarez; Claudia Marcela Rivera-Hoyos; Angélica María Baena-Moncada; Patricia Landázuri; Raúl A Poutou-Piñales; Homero Sáenz-Suárez; Luis A Barrera; Olga Y Echeverri-Peña
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

5.  A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.

Authors:  Yo Kyung Chung; Young Bae Sohn; Jong Mun Sohn; Jieun Lee; Mi Sun Chang; Younghee Kwun; Chi Hwa Kim; Jin Young Lee; Yeon Joo Yook; Ah-Ra Ko; Dong-Kyu Jin
Journal:  Glycoconj J       Date:  2014-04-30       Impact factor: 2.916

6.  Analysis of normal and mutant iduronate-2-sulphatase conformation.

Authors:  Emma Parkinson-Lawrence; Christopher Turner; John Hopwood; Doug Brooks
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

7.  Hunter syndrome: presence of material cross-reacting with antibodies against iduronate sulfatase.

Authors:  A Daniele; P Di Natale
Journal:  Hum Genet       Date:  1987-03       Impact factor: 4.132

8.  Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.

Authors:  Vinicia Assunta Polito; Serena Abbondante; Roman S Polishchuk; Edoardo Nusco; Rosaria Salvia; Maria Pia Cosma
Journal:  Hum Mol Genet       Date:  2010-09-27       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.